GO-010: Neoantigen Vaccine GRT-C901/GRT-R902 as Maintenance After First Line Metastatic Therapy
Condition: Colon or Rectal Cancer
Sponsor: Gritstone bio, Inc.
Protocol GO-010: A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
GRT-C901/GRT-R902 neoantigen vaccine in combination with ipilimumab, nivolumab, and standard maintenance chemotherapy for patients with stage IV colorectal cancer and stable disease after first line treatment with FOLFOX or CAPEOX plus bevacizumab.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.